CRXT
Price:
$0.099
Market Cap:
$0
Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeut...[Read more]
Industry
Drug Manufacturers - General
IPO Date
2021-09-07
Stock Exchange
NASDAQ
Ticker
CRXT
According to Clarus Therapeutics Holdings, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 15.85M. This represents a change of -63.36% compared to the average of 43.27M of the last 4 quarters.
The mean historical Enterprise Value of Clarus Therapeutics Holdings, Inc. over the last ten years is 122.50M. The current 15.85M Enterprise Value has changed 1.19% with respect to the historical average. Over the past ten years (40 quarters), CRXT's Enterprise Value was at its highest in in the June 2021 quarter at 321.37M. The Enterprise Value was at its lowest in in the September 2020 quarter at 0.
Average
122.50M
Median
122.50M
Minimum
74.24M
Maximum
170.76M
Discovering the peaks and valleys of Clarus Therapeutics Holdings, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual Enterprise Value = 170.76M
Minimum Annual Increase = -56.53%
Minimum Annual Enterprise Value = 74.24M
Year | Enterprise Value | Change |
---|---|---|
2021 | 74.24M | -56.53% |
The current Enterprise Value of Clarus Therapeutics Holdings, Inc. (CRXT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
122.50M
5-year avg
122.50M
10-year avg
122.50M
Clarus Therapeutics Holdings, Inc.’s Enterprise Value is
Company | Enterprise Value | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Clarus Therapeutics Holdings, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Clarus Therapeutics Holdings, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Clarus Therapeutics Holdings, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Clarus Therapeutics Holdings, Inc. (CRXT)?
What is the 3-year average Enterprise Value for Clarus Therapeutics Holdings, Inc. (CRXT)?
What is the 5-year average Enterprise Value for Clarus Therapeutics Holdings, Inc. (CRXT)?
How does the current Enterprise Value for Clarus Therapeutics Holdings, Inc. (CRXT) compare to its historical average?